ZNTL Zentalis Pharmaceuticals
- 12.340
- -0.180-1.44%
Zentalis Pharmaceuticals News
Assessing Zentalis Pharmaceuticals: A Balanced Hold Rating Amidst Financial Stability and Uncertain Market Prospects
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $46 to $40.
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
Zentalis Pharmaceuticals (ZNTL) has an average outperform rating and a price target range of $15 to $50, according to analysts polled by Capital IQ. Price: 12.06, Change: -0.25, Percent Change: -2.03
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) instance, it's good news for shareholders.
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Is Maintained at Buy by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Zentalis Pharmaceuticals Price Target Cut to $32.00/Share From $36.00 by Stifel
Stifel Maintains Buy on Zentalis Pharma, Lowers Price Target to $32
Stifel analyst Bradley Canino maintains Zentalis Pharma with a Buy and lowers the price target from $36 to $32.
Zentalis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 159.95% Stifel $36 → $32 Maintains Buy 02/28/2024 273.68% HC Wainwright & Co. → $46 Reiterates
Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts With Strategic ...
Zentalis Pharma's Q1 Cash, Cash Equivalents and Marketable Securities Position Of $489M Is Expected To Provide Cash Runway Into Mid-2026
Zentalis Pharma's Q1 Cash, Cash Equivalents and Marketable Securities Position Of $489M Is Expected To Provide Cash Runway Into Mid-2026
Zentalis Pharma Q1 2024 GAAP EPS $0.14 May Not Be Comparable To $(0.73) Estimate, Sales $40.560M May Not Be Comparable To $13.125M Estimate
Zentalis Pharma Q1 2024 GAAP EPS $0.14 May Not Be Comparable To $(0.73) Estimate, Sales $40.560M May Not Be Comparable To $13.125M Estimate
Zentalis Pharmaceuticals | 10-Q: Quarterly report
Zentalis Pharmaceuticals 1Q EPS 14c >ZNTL
Zentalis Pharmaceuticals 1Q EPS 14c >ZNTL
Press Release: Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress Azenosertib clinical development plan on track with multiple data readouts in gynecological and other ca
Analysis
Price Target
No Data
